

# SCORE2 on the MESI mTABLET



## What it is

**SCORE2** is a free MESI mTABLET feature that automatically calculates SCORE2 or SCORE2-OP for each patient aged 40 and over.

### SCORE2

is a risk prediction algorithm that estimates a 10-year **risk of fatal and non-fatal CVD events** in seemingly healthy individuals aged 40 and over.

### SCORE2-OP

is a risk prediction algorithm used for **persons above 69 years** of age.



# Why you should use SCORE2

SCORE2 enables **better and faster review of the health status and cardiovascular risk** of patients in the MESI mTABLET system, ensuring quality patient management.



Patient 1



Patient 2



Patient 3

	<50 years	50-69 years	≥70 years
●	<2.5%	<5%	<7.5%
●	2.5-7.5%	5-10%	7.5-15%
●	≥7.5%	≥10%	≥15%

Based on its results, healthcare professionals can **effectively manage CVD prevention**.

In addition to the risk assessment, they can obtain **important information about the patient's health condition** and possible recommendations.

## How it works

SCORE2 is calculated based on the **age, sex, country, systolic blood pressure, non-HDL cholesterol, and smoking status** of the patient.

If some (or all) vital patient data is missing for the calculation, **the system suggests that the medical professional should enter it**. This is also the case when a new profile is created for a patient aged 40 or more.

SCORE2 and SCORE2-OP charts do not apply to patients with diagnosed **diabetes mellitus II** or **past cardiovascular events**.

### SCORE2 / SCORE2-OP ⓘ


Calculation valid for patients with no previous cardiovascular event or type 2 diabetes.

**FILL OUT MISSING DATA**

To get a SCORE2/OP, you need to enter info on smoking, blood pressure and cholesterol.


**COUNTRY** Slovenia  
**AGE** 82  
**SEX** Female  
**BP** -  
**non-HDL** -  
**SMOKING** -

PREDICTIVE MEDICAL ASSESSMENT



## Where it is used

SCORE2 and SCORE2-OP are used for the countries listed below. **The countries were grouped into four risk regions** according to their most recently reported WHO age- and sex-standardised overall CVD mortality rates per 100,000 population.



### LOW CVD risk countries

Belgium, Denmark, France, Israel, Luxembourg, Norway, Spain, Switzerland, the Netherlands, and the United Kingdom (UK).

### MODERATE CVD risk countries

Austria, Cyprus, Finland, Germany, Greece, Iceland, Ireland, Italy, Malta, Portugal, San Marino, Slovenia, and Sweden.

### HIGH CVD risk countries

Albania, Bosnia and Herzegovina, Croatia, Czechia, Estonia, Hungary, Kazakhstan, Poland, Slovakia, and Turkey.

### VERY HIGH CVD risk countries

Algeria, Armenia, Azerbaijan, Belarus, Bulgaria, Egypt, Georgia, Kyrgyzstan, Latvia, Lebanon, Libya, Lithuania, Moldova, Montenegro, Morocco, North Macedonia, Romania, the Russian Federation, Serbia, Syria, Tunisia, Ukraine, and Uzbekistan.

#### SOURCE:


Frank L J Visseren, François Mach, Yvo M Smulders, David Carballo, Konstantinos C Koskinas, Maria Bäck, Athanase Benetos, Alessandro Biffi, José-Manuel Boavida, Davide Capodanno, Bernard Cosyns, Carolyn Crawford, Constantinos H Davos, Ileana Desormais, Emanuele Di Angelantonio, Oscar H Franco, Sigrun Halvorsen, F D Richard Hobbs, Monika Hollander, Ewa A Jankowska, Matthias Michal, Simona Sacco, Naveed Sattar, Lale Tokgozoglou, Serena Tonstad, Konstantinos P Tsioufis, Ineke van Dis, Isabelle C van Gelder, Christoph Wanner, Bryan Williams, ESC Scientific Document Group. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice: Developed by the Task Force for cardiovascular disease prevention in clinical practice with representatives of the European Society of Cardiology and 12 medical societies with the special contribution of the European Association of Preventive Cardiology (EAPC), European Heart Journal, Volume 42, Issue 34, 7 September 2021, pp. 3227–3337. <https://doi.org/10.1093/eurheartj/ehab484>

## How to select the country

On the MESI mTABLET, SCORE2 is calculated based on the country the person lives in. The country used for calculation is the one that is **selected as the location country for the MESI mTABLET** when the medical professional first starts using it.

Due to the introduction of SCORE2, **the system now asks current MESI mTABLET users to confirm the country** where they use their MESI mTABLET. Please note that the selected country can no longer be changed afterwards.

**New MESI mTABLET users select their country upon their first use** of the MESI mTABLET. Please note that the selected country can no longer be changed afterwards.




## Where to find SCORE2 results

After entering the data, the **calculated score is displayed on the patient's SCORE2 screen**, highlighting all the factors used in the calculation.

SCORE2 is also visible in the **patient list** as well as in the **doctor's archive** and the **patient's profile**.

BD	Babic, David Male, age 73	54 SCORE2
BE	Backs, Emily Female, age 55	14 SCORE2
CA	Chamberlain, Alex Male, age 49	4 SCORE2



MESI, Ltd.  
Leskoškova cesta 11a  
1000 Ljubljana,  
Slovenia, EU

E: [info@mesimedical.com](mailto:info@mesimedical.com)  
T: +386 1 620 34 87

[www.mesimedical.com](http://www.mesimedical.com)

MESIdoo

MESImedical

MESI



European production  
and development



Worldwide presence

FDA

Food and Drug  
Administration  
cleared

MDR

EU Medical Device  
Regulations  
compliant



ISO 9001 Q-1664  
ISO 13485 M-049

ISO 9001 and  
ISO 13485 certified



MDSAP compliant